Skip to Content
Merck
All Photos(1)

Documents

1370462

USP

Losartan potassium

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-Butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl]methyl}-1H-imidazole-5-methanol monopotassium salt, 2-butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-methanol potassium salt, DuP 753, MK 954, Potassium 5-(4′-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)tetrazol-1-ide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H22ClKN6O
CAS Number:
Molecular Weight:
461.00
Beilstein:
5845770
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

losartan

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]

InChI

1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

InChI key

OXCMYAYHXIHQOA-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

General description

Losartan potassium is a new drug used for hypertension. It is nonpeptide angiotensin II (AII) receptor antagonist.
Losartan potassium is nonpeptide angiotensin II (AII) receptor antagonist and is orally active. It belongs to a new class of drugs introduced for clinical trials to treat hypertension.

Application

Losartan potassium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Losartan Potassium and Hydrochlorothiazide Tablets
  • Losartan Potassium Tablets

Biochem/physiol Actions

Losartan potassium is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan potassium is used for treatment of hypertension.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Quantification of losartan and its metabolite in rat urine
Prolina, OG, et al.
Bulletin of Moscow University, 53.3, 194-197 (2012)
D M Dorfman et al.
The Journal of biological chemistry, 267(2), 1279-1285 (1992-01-15)
Previously, we showed that the promoter of the gene encoding preproendothelin-1 (PPET-1) contains a GATA motif that is essential for activity and interacts with a nuclear factor similar in size and binding specificity to the erythroid transcription factor GATA-1. To
M Burnier et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)
The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose
L M Burrell
Drug safety, 16(1), 56-65 (1997-01-01)
Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which
Tetsuhiro Kakimoto et al.
The Journal of endocrinology, 222(1), 43-51 (2014-05-02)
Diabetic nephropathy is a major complication in diabetes and a leading cause of end-stage renal failure. Glomerular podocytes are functionally and structurally injured early in diabetic nephropathy. A non-obese type 2 diabetes model, the spontaneously diabetic Torii (SDT) rat, is

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service